Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037620 | PMC |
| http://dx.doi.org/10.1155/2014/864062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chlorin e6: a promising photosensitizer of anti-tumor and anti-inflammatory effects in PDT.
Nanomedicine (Lond)
January 2025
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
Photodynamic therapy (PDT) involves the activation of photosensitizers (PSs) by visible laser light at the target site to catalyze the production of reactive oxygen species, resulting in tumor cell death and blood vessel closure. The efficacy of PDT depends on the PSs, the amount of oxygen, and the intensity of the excitation laser. PSs have been extensively researched, and great efforts have been made to develop an ideal photosensitizer.
View Article and Find Full Text PDFRelationship between ferroptosis and healing of diabetic foot ulcer: a prospective clinical study.
Front Endocrinol (Lausanne)
January 2025
Department of Plastic Surgery, the First Affiliated Hospital of Air Force Medical University, Xi'an, China.
Objective: Diabetic foot ulcer (DFU) is one of the common complications in patients with diabetes mellitus (DM). In order to find a method to monitor and treat the refractory DFU, the ferroptosis level in DFU and traumatic wounds (TW) was monitored and the difference between them was analyzed. At the same time, this study further analyzed the correlation of ferroptosis levels with DM severity and DFU's healing.
View Article and Find Full Text PDFElafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model.
World J Gastroenterol
January 2025
Carmen Laboratory, INSERM Unit 1060-Lyon 1 University, Pierre Benite 69310, France.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent liver pathology in need of novel pharmacological treatments to complement lifestyle-based interventions. Nuclear receptor agonists have been under scrutiny as potential pharmacological targets and as of today, resmetirom, a thyroid hormone receptor b agonist, is the only approved agent. The dual PPAR α and δ agonist elafibranor has also undergone extensive clinical testing, which reached the phase III clinical trial but failed to demonstrate a beneficial effect on MASLD.
View Article and Find Full Text PDFNDUFA11 may be the disulfidptosis-related biomarker of ischemic stroke based on integrated bioinformatics, clinical samples, and experimental analyses.
Front Neurosci
January 2025
Department of Geriatric Rehabilitation, Jiangbin Hospital, Nanning, China.
Background: Programmed cell death plays an important role in neuronal injury and death after ischemic stroke (IS), leading to cellular glucose deficiency. Glucose deficiency can cause abnormal accumulation of cytotoxic disulfides, resulting in disulfidptosis. Ferroptosis, apoptosis, necroptosis, and autophagy inhibitors cannot inhibit this novel programmed cell death mechanism.
View Article and Find Full Text PDFAssociation between D-dimer to lymphocyte ratio and in hospital all-cause mortality in elderly patients with sepsis: a cohort of 1123 patients.
Front Cell Infect Microbiol
January 2025
Department of Critical Care Medicine, The Affiliated Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
Background: The D-dimer to lymphocyte ratio (DLR), a novel inflammatory biomarker, had been shown to be related to adverse outcomes in patients with various diseases. However, there was limited research on the relationship between the DLR and adverse outcomes in patients with infectious diseases, particularly those with sepsis. Therefore, this study aimed to explore the association between the DLR and in hospital all-cause mortality in elderly patients with sepsis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!